Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia.
Barneh F, Koedijk JB, Wijnen NE, Meulendijks T, Ashtiani M, Dunnebach E, Dautzenberg N, Cornel AM, Krippner-Heidenreich A, Klein K, Zwaan MC, Kuball J, Nierkens S, Cloos J, Kaspers GJL, Heidenreich O. Barneh F, et al. Among authors: kuball j. Haematologica. 2024 Dec 1;109(12):4131-4136. doi: 10.3324/haematol.2024.285707. Haematologica. 2024. PMID: 39113654 Free PMC article. No abstract available.
BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response.
Alieva M, Barrera Román M, de Blank S, Petcu D, Zeeman AL, Dautzenberg NMM, Cornel AM, van de Ven C, Pieters R, den Boer ML, Nierkens S, Calkoen FGJ, Clevers H, Kuball J, Sebestyén Z, Wehrens EJ, Dekkers JF, Rios AC. Alieva M, et al. Among authors: kuball j. Nat Protoc. 2024 Jul;19(7):2052-2084. doi: 10.1038/s41596-024-00972-6. Epub 2024 Mar 19. Nat Protoc. 2024. PMID: 38504137 Review.
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V, Meringa A, Dunnebach E, van Velzen A, Moreira AV, Stam RW, Kotecha RS, Krippner-Heidenreich A, Heidenreich OT, Plantinga M, Cornel A, Sebestyen Z, Kuball J, van Til NP, Nierkens S. Lo Presti V, et al. Among authors: kuball j. J Immunother Cancer. 2024 Apr 5;12(4):e008174. doi: 10.1136/jitc-2023-008174. J Immunother Cancer. 2024. PMID: 38580329 Free PMC article.
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Garderet L, Gras L, Koster L, De Wreede L, Montserrat R, Vincent L, Fenk R, Karunanithi K, Deeren D, Kaufmann M, Kuball J, Ozdogu H, Cascon MJP, Passweg J, Rye A, Salmenniemi U, Snowden J, Hansen CT, Leleu X, Gastaud L, Sokolowska JD, Raj K, Beksac M, Schönland S, Hayden P, McLornan D. Garderet L, et al. Among authors: kuball j. Haematologica. 2024 Aug 1;109(8):2619-2627. doi: 10.3324/haematol.2023.284520. Haematologica. 2024. PMID: 38546696 Free PMC article.
Busulfan Exposure Target Attainment in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation: A Single Day Versus a Multiple Day Therapeutic Drug Monitoring Regimen.
Bognàr T, Bartelink IH, van der Elst KCM, Kingma JS, Smeijsters EH, Lindemans CA, Egberts ACG, Kuball JHE, de Witte MA, Schultink AHMV, Lalmohamed A. Bognàr T, et al. Among authors: kuball jhe. Transplant Cell Ther. 2024 Oct;30(10):1007.e1-1007.e10. doi: 10.1016/j.jtct.2024.07.015. Epub 2024 Jul 25. Transplant Cell Ther. 2024. PMID: 39067789 Free article.
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit.
Johanna I, Daudeij A, Devina F, Nijenhuis C, Nuijen B, Romberg B, de Haar C, Haanen J, Dolstra H, Bremer E, Sebestyen Z, Straetemans T, Jedema I, Kuball J. Johanna I, et al. Among authors: kuball j. Immunooncol Technol. 2023 Oct 14;20:100411. doi: 10.1016/j.iotech.2023.100411. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 38192616 Free PMC article. Review.
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Ossenkoppele GJ, et al. Leukemia. 2020 Jul;34(7):1751-1759. doi: 10.1038/s41375-020-0725-0. Epub 2020 Feb 4. Leukemia. 2020. PMID: 32020044 Clinical Trial.
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Ossenkoppele GJ, et al. Leukemia. 2020 Oct;34(10):2820. doi: 10.1038/s41375-020-0994-7. Leukemia. 2020. PMID: 32733013
Reactivation of Multidrug-Resistant HSV-1 in a Post-Allogenic Hematopoietic Stem Cell Transplant Patient: Dynamic Detection of the Rare A605V Mutation by Next-Generation Sequencing.
Zheng S, Rümke LLW, Tello Rubio B, Rogers MRC, van Sluis GL, Kuball JHE, Riezebos-Brilman A, Lebbink RJ, Verduyn Lunel FM. Zheng S, et al. Open Forum Infect Dis. 2024 May 3;11(5):ofae250. doi: 10.1093/ofid/ofae250. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38798899 Free PMC article.
229 results